Daunorubicin/Cytarabine

柔红霉素/阿糖胞苷

Report date: 2026/05/26 20:00:28

Base Information

Drug NameDaunorubicin/Cytarabine
Drug Alias NameDaunorubicin and Cytarabine阿糖胞苷/柔红霉素Cytarabine/Daunorubicincytarabine + daunorubicinVyxeos +[8] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analoguesSmall molecules > Heterocyclic drugs > Antibiotics > Anthracycline antibiotics
Mechanisms of ActionDNA-directed DNA polymerase inhibitorsDNA synthesis inhibitorsTopoisomerase II inhibitors
TargetsTopoisomerase IIDNA-directed DNA polymerase
Therapy Area/IndicationsMyelodysplastic SyndromesHematologic NeoplasmsLymphoma, Large-Cell, Anaplastic +[16] 
Global Approved IndicationsLeukemia, Myeloid, Acute
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2017/08/03
Country/TerritoryCanadaUnited StatesPoland +[10] 
CombinationsYes Daunorubicin HydrochlorideCytarabine
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesJazz Pharmaceuticals Plc
China Registration ClassN/A

Develop Information

Active CompaniesJazz Pharmaceuticals Therapeutics IncWeill Medical College of Cornell UniversityGwt-Tud Gmbh +[12] 
Inactive CompaniesGeorgetown UniversityRoswell Park Cancer InstituteYale University +[5] 
Active IndicationsMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute +[5] 
Inactive IndicationsHematologic NeoplasmsLymphoma, Large-Cell, AnaplasticLymphoma, Large B-Cell, Diffuse +[11] 

Other Information

ATC CodeL01XY01
Related LinksN/A